ManufacturingACHIEVEApproved
USFDA issues EIR closing inspection of Strides Pharma manufacturing facility in Bengaluru
Bengaluru, Karnataka20 Aug 2026
Strides Pharma Science Ltd said its flagship manufacturing facility in Bengaluru received an Establishment Inspection Report (EIR) from the USFDA, marking closure of a cGMP inspection conducted May 12–20, 2026. The inspection outcome was classified as Voluntary Action Indicated (VAI) after the company responded to a Form 483 with five observations and implemented corrective and preventive actions.
Why it matters
USFDA inspection closure supports the Bengaluru plant’s ability to supply regulated international markets with finished pharmaceutical dosage forms.
Strides Pharma Science LimitedU.S. Food and Drug Administration (USFDA)